Patent intelligence · AU
AU 2002363847
1-ALLYL ERGOT ALKALOID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF FOR PREVENTING AND TREATING MIGRAINE
1-ALLYL ERGOT ALKALOID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF FOR PREVENTING AND TREATING MIGRAINE
Patent details — AU 2002363847
- Jurisdiction
- AU
- Status
- expired
- Grant date
- Sep 22, 2003
- Expiration
- Sep 17, 2023
- Applicant
- AXXONIS PHARMA AG [DE]
- CPC classes
- A61P 43/ 00 A I, A61P/2500, A61P/2506, A61P/2516
Quick answer
AU 2002363847 (1-ALLYL ERGOT ALKALOID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF FOR PREVENTING AND TREATING MIGRAINE) is held by AXXONIS PHARMA AG [DE]. Status: expired. Granted Sep 22, 2003. Expires Sep 17, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AXXONIS PHARMA AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P 43/ 00 A I, A61P/2500, A61P/2506, A61P/2516, A61P/4300, A61P/702
More from AXXONIS PHARMA AG [DE]
Related pharmaceutical patents in our USPTO index.
-
CA 2626142
SOLUTIONS AQUEUSES STABILISEES DE COMPOSES D'ERGOLINE
granted -
DE 102006048130
Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil
granted -
IT MI20070164
CEROTTO TRANSDERMICO
granted -
DE 102004006048
Pharmazeutische Kombination aus Gadolinium Komplexen und kolloidalen Biopolymeren und deren Verwendung als kontrastverstärkendes Mittel zur i.v. Injektion bzw. i.v. Infusion in der MR Angiographie
expired -
DE 10341317
Mittel zur transdermalen Applikation
expired -
EP 1311248
TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES RESTLESS-LEGS-SYNDROMS
expired -
EP 1303278
KOMBINATION EINES TRANSDERMALEN THERAPEUTISCHEN SYSTEMS UND EINER ORALEN UND/ODER PARENTERALEN ZUBEREITUNG ENTHALTEND DOPAMINAGONISTEN ZUR BEHANDLUNG DOPAMINERGER ERKRANKUNGEN
expired
Frequently asked questions
What is US patent 2002363847?
AU 2002363847 (1-ALLYL ERGOT ALKALOID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF FOR PREVENTING AND TREATING MIGRAINE) is held by AXXONIS PHARMA AG [DE]. Status: expired. Granted Sep 22, 2003. Expires Sep 17, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2002363847?
AXXONIS PHARMA AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does AU 2002363847 expire?
Our index shows an expiration date of Sep 17, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.